Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
CAPTURE Results by Troponin T Status Death or Nonfatal MI through 6 Months % of Pts., Death/MI 10 8 6 4 2 TnT < 0.2 ng/ml - 6 Months Placebo n=686 Abciximab* 30 25 20 15 10 5 TnT > 0.2 ng/ml - 6 Months Placebo Abciximab* 64% ↓ p = 0.005 0 0 0 30 60 90 120 150 180 0 Days * 0.25 mg/kg bolus followed by a 10 ug/min infusion until PCI; continue infusion for 1 hour post-PCI 022200.1Budden os 3 30 60 90 120 150 180 Days Circulation 2000; 101:570-80
TIMI Risk Score For UA/NSTEMI • Age ≥ 65 years C Statistic=0.65 χ2 trend P50 % • ST deviation • ≥ 2 anginal events ≤ 24 hours • ASA in last 7 days • Elevated cardiac markers (CK-MB or troponin) D/MI/Urg Revasc (%) 50 40 30 20 10 0 40.9 26.2 19.9 13.2 8.3 4.7 0/1 2 3 4 5 6/7 Number of Risk Factors Population (%): 4.3 17.3 32.0 29.3 13.0 3.4 Antman EM, et al. JAMA. 2000;284:835-442
- Page 1 and 2: P come piastrine, come prezzemolo
- Page 3 and 4: Formazione del trombo nelle ACS sen
- Page 5 and 6: GP IIb-IIIa Inhibitors costituiscon
- Page 8 and 9: Cardiologia “De Gasperis”- Nigu
- Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
- Page 12: Characteristics of GP IIb/IIIa Inhi
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
- Page 24 and 25: % of Patients IIb/IIIa Inhibition w
- Page 26 and 27: GP IIb/IIIa Inhibitor During Medica
- Page 28 and 29: Peterson E.D.et al.: Early use of g
- Page 30 and 31: ISAR-COOL study - Pre-procedural ou
- Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
- Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
- Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
- Page 42 and 43: Coronarografia in base a età e TIM
- Page 44 and 45: Sindromi Coronariche Acute ST-segme
- Page 46 and 47: Occlusive thrombus contains Fibrin
- Page 48 and 49: Abciximab Improves ST Res-90 min ST
- Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
- Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
- Page 54 and 55: BMS and abciximab display a synergi
- Page 56 and 57: Study design Inclusion Criteria: ST
- Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
- Page 60 and 61: GUSTO V AMI GUSTO V - Trial Schemat
- Page 62 and 63: IIb/IIIa Varie...ed eventuali
- Page 64 and 65: IIb/IIIa e PCI: Nei pazienti stabil
- Page 66: Conclusioni Glycoprotein IIb/IIIa I
TIMI Risk Score For UA/NSTEMI<br />
• Age ≥ 65 years<br />
C Statistic=0.65<br />
χ2 trend P50 %<br />
• ST deviation<br />
• ≥ 2 anginal<br />
events ≤ 24 hours<br />
• ASA in last 7 days<br />
• Elevated cardiac<br />
markers (CK-MB or<br />
troponin)<br />
D/MI/Urg Revasc (%)<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
40.9<br />
26.2<br />
19.9<br />
13.2<br />
8.3<br />
4.7<br />
0/1 2 3 4 5 6/7<br />
Number of Risk Factors<br />
Population (%): 4.3 17.3 32.0 29.3 13.0 3.4<br />
Antman EM, et al. JAMA. 2000;284:835-442
Change language